Boehringer Ingelheim is a research-driven pharmaceutical company which focuses on the research, development, production and distribution of new medicines for unmet medical needs in people and animals. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Boehringer Ingelheim was founded in 1885 by Albert Boehringer and has been family-owned ever since. It is the stated goal of the shareholders and the management to remain an independent family business. The international headquarters are located in Ingelheim am Rhein, Germany.
In addition to the Ingelheim headquarters, Boehringer Ingelheim also has other German sites in Biberach (Baden-Württemberg), Dortmund and Hanover. In total, the company employs some 15,000 people in Germany, including more than 600 apprentices.
In its research and development activities in human medicine Boehringer Ingelheim concentrates on the following areas: cardiovascular and metabolic diseases, respiratory diseases, diseases of the central nervous system, diseases of the immune system and oncology.
The focus is on human and animal health, so Boehringer Ingelheim's goal is to cure or alleviate diseases and to improve quality of life. A focus in animal health is disease prevention.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the global health initiative Making More Health. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.